CompletedPhase 1NCT06831812

Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nuravax, Inc.
Principal Investigator
Roman Kniazev
Nuravax, Inc.
Intervention
AV-1959R (Abeta vaccine)(biological)
Enrollment
16 target
Eligibility
40-60 years · All sexes
Timeline
20242025

Study locations (1)

Collaborators

Arvax

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06831812 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials